compound
Retatrutide (12mg Vial) Questions Answered
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors [1] , studied for substantial weight loss and metabolic improvement in obesity and type 2 diabetes [2] [3] .
Retatrutide (12mg Vial)
Week(s) Weekly Dose (mg) Units (mL) Weeks 1–4 2 mg 20 units (0.20 mL) Weeks 5–8 4 mg 40 units (0.40 mL) Weeks 9–12 8 mg 80 units (0.80 mL) Weeks 13+ 12 mg 120 units (1.20 mL) Frequency: Inject once weekly subcutaneously.
Retatrutide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors [1] , studied for substantial weight loss and metabolic improvement in obesity and type 2 diabetes [2] [3] .
Week(s) Weekly Dose (mg) Units (mL) Weeks 1–4 2 mg 20 units (0.20 mL) Weeks 5–8 4 mg 40 units (0.40 mL) Weeks 9–12 8 mg 80 units (0.80 mL) Weeks 13+ 12 mg 120 units (1.20 mL) Frequency: Inject once weekly subcutaneously.
Plan based on a 12–48 week weekly protocol with gradual titration to maintenance dose.
Proper storage maintains peptide stability and potency. Lyophilized: Store at −20 °C (−4 °F) or colder for long-term preservation; protect from moisture and light [11] [12] .